188 related articles for article (PubMed ID: 18775019)
1. Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Hur C; Broughton DE; Ozanne E; Yachimski P; Nishioka NS; Gazelle GS
Am J Gastroenterol; 2008 Oct; 103(10):2432-42. PubMed ID: 18775019
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention and Barrett's esophagus: decisions, decisions.
Falk GW; Jankowski J
Am J Gastroenterol; 2008 Oct; 103(10):2443-5. PubMed ID: 18775008
[TBL] [Abstract][Full Text] [Related]
3. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
Heath EI; Canto MI; Piantadosi S; Montgomery E; Weinstein WM; Herman JG; Dannenberg AJ; Yang VW; Shar AO; Hawk E; Forastiere AA;
J Natl Cancer Inst; 2007 Apr; 99(7):545-57. PubMed ID: 17405999
[TBL] [Abstract][Full Text] [Related]
4. Patient preferences for the chemoprevention of colorectal cancer.
Hur C; Broughton DE; Kong CY; Ozanne EM; Richards EB; Truong T; Gazelle GS
Dig Dis Sci; 2009 Oct; 54(10):2207-14. PubMed ID: 19057995
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
Bresalier RS
Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
[TBL] [Abstract][Full Text] [Related]
6. Current Status of Chemoprevention in Barrett's Esophagus.
Moayyedi P; El-Serag HB
Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
[TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
8. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C
Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852
[TBL] [Abstract][Full Text] [Related]
9. [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].
Zhang T; Su LW; Zhu YF; Lang HJ; Zhang F; Zhou YA; Liang XH; Wang YJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 May; 15(5):512-6. PubMed ID: 22648851
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Wang F; Lv ZS; Fu YK
Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention in Barrett's oesophagus.
Gordon V; Jankowski J
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):569-79. PubMed ID: 22122772
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Chen X; Wang S; Wu N; Sood S; Wang P; Jin Z; Beer DG; Giordano TJ; Lin Y; Shih WC; Lubet RA; Yang CS
Clin Cancer Res; 2004 Oct; 10(19):6703-9. PubMed ID: 15475461
[TBL] [Abstract][Full Text] [Related]
14. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
Gatenby PA; Ramus JR; Caygill CP; Winslet MC; Watson A
Eur J Cancer Prev; 2009 Sep; 18(5):381-4. PubMed ID: 19620873
[TBL] [Abstract][Full Text] [Related]
15. Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus.
Yachimski P; Wani S; Givens T; Howard E; Higginbotham T; Price A; Berman K; Hosford L; Katcher PM; Ozanne E; Perzan K; Hur C
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):84-90. PubMed ID: 24681073
[TBL] [Abstract][Full Text] [Related]
16. Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.
Liu FX; Wang WH; Wang J; Li J; Gao PP
Helicobacter; 2011 Feb; 16(1):66-77. PubMed ID: 21241415
[TBL] [Abstract][Full Text] [Related]
17. [Medical treatment of Barrett's esophagus].
Kinoshita Y; Yuki T
Nihon Rinsho; 2005 Aug; 63(8):1449-53. PubMed ID: 16101238
[TBL] [Abstract][Full Text] [Related]
18. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.
Nguyen T; Duan Z; Naik AD; Kramer JR; El-Serag HB
Gastroenterology; 2015 Nov; 149(6):1392-8. PubMed ID: 26208896
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention in Barrett's esophagus: A pill a day?
Jankowski JA; Hooper PA
Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):155-70. PubMed ID: 21112505
[TBL] [Abstract][Full Text] [Related]
20. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
